CD274 and neoplasm: Among patients with PD-L1–evaluable tumors, PD-L1 expression (immune cell [IC]0 and tumor cell [TC]0 [<1%]; IC1 or TC1 [≥1% but <5%]; TC2 [≥5% but <50%]) was observed in eight of 15 patients (53.3%) at baseline (Supplementary Fig. 4).